![A line drawing of a laptop and a cup of coffee](/sites/default/files/2020-12/hero-laptop.png)
This resource describes how state health departments and other public health organizations can partner with people with HIV and/or who use(d) drugs in programmatic and policy making processes and evaluation.
This resource describes how state health departments and other public health organizations can partner with people with HIV and/or who use(d) drugs in programmatic and policy making processes and evaluation.
Articles in this supplement focus on the global opioid crisis, including coverage of harm reduction approaches, health justice promotion, and lessons learned.
The COVID-19 pandemic resulted in federal policy changes related to telehealth use that allowed states to maximize access to medications for opioid use disorder (MOUD) through telehealth.
Individuals who have HIV who also use drugs experience increased age-matched morbidity and mortality in comparison with those with HIV who do not use drugs.
This webinar companion guide offers attendees a resource to supplement the information covered during a webinar and extend the webinar’s benefits beyond the allotted presentation time. It contains:
A recent study published in Drug and Alcohol Dependence found evidence for racial/ethnic disparities in buprenorphine distribution across the United States.
This document provides a quick overview of the federal discretionary funding programs that support essential aspects of the nation’s HIV response.
In recent years, the gap in the rate of opioid overdoses among Black and white Americans has narrowed significantly, with increases in Black mortality driven in part by the addition of synthetic opioids to other drugs.
Achieving the goals of the Ending the HIV Epidemic (EHE) Initiative depends on doing more to strengthen communities, reduce the harm associated with drug use, and prevent disease transmission.